Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
NORTH BILLERICA, Mass., Sept. 01, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that Bob Marshall, CFO, and Paul Blanchfield, COO, will present at the Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET. The presentation will focus on the company’s commitment to innovative diagnostics and therapeutics, including artificial intelligence solutions that enhance patient outcomes. A live webcast can be accessed through the Investors section of the company's website, with a replay available for 30 days.
Lantheus Holdings reported $223.7 million in worldwide revenue for Q2 2022, marking a 121.4% increase from Q2 2021. The company achieved a GAAP net income of $43.1 million, or $0.61 per diluted share, compared to a net loss of $26.7 million in the previous year. Adjusted fully diluted EPS increased to $0.89 from $0.11. Net cash provided by operating activities was $72.6 million, with free cash flow at $68.3 million. The company has raised its full-year revenue guidance to between $885 million and $905 million.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced it will host a conference call and webcast on August 4, 2022, at 8:00 a.m. ET to discuss its second-quarter 2022 financial and operating results. Interested participants should register in advance to avoid delays. A replay will be available shortly after the event and archived for at least 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions.
Lantheus Holdings has announced key management promotions, with Paul Blanchfield becoming Chief Operating Officer and Dottie Barr promoted to Senior Vice President, Manufacturing and Technical Operations. Effective immediately, these changes aim to leverage their expertise for enhanced strategic execution and patient outcomes. Blanchfield, previously Chief Commercial Officer, is recognized for his role in launching the PSMA PET imaging agent for prostate cancer, while Barr has successfully led manufacturing and supply chain improvements despite pandemic challenges.
Lantheus Holdings presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the SNMMI Annual Meeting. The study focuses on NM-01, a technetium 99m SPECT/CT imaging agent, which aims to assess PD-L1 expression in cancer cells. Preliminary findings indicate that NM-01 can identify patients likely to respond to checkpoint inhibitor therapies, particularly in non-small cell lung cancer (NSCLC). The study included 10 patients, revealing significant insights into PD-L1 expression and treatment response, suggesting NM-01 could enhance patient selection and monitoring in clinical settings.
Lantheus Holdings presented results at the SNMMI Annual Meeting, showcasing the effectiveness of PYLARIFY AI, an FDA-cleared AI platform for PSMA PET/CT scans in prostate cancer. The study highlighted its ability to enhance lesion detection and quantitative assessment compared to manual readings, with significant improvements in diagnostic accuracy and efficiency. The findings reaffirm Lantheus's commitment to integrating AI in oncology, potentially transforming prostate cancer management and improving patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, CEO, and Bob Marshall, CFO, will present at the Jefferies Healthcare Conference on June 9 at 11:00 a.m. ET. The event will take place in New York City, showcasing the company's commitment to innovative imaging diagnostics and therapeutics. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 30 days post-event. Lantheus is a leader in advanced medical imaging solutions, aiming to enhance patient care through its diverse product portfolio.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced key presentations at the 2022 SNMMI Meeting in Vancouver, scheduled for June 11-14, 2022. The event will feature oral presentations on two significant imaging agents: PYLARIFY® (piflufolastat F18) for prostate cancer and PYLARIFY AI™, an AI platform for PSMA PET imaging. PYLARIFY's efficacy will be discussed concerning androgen deprivation therapies, while PYLARIFY AI™ will highlight a Phase III study aimed at rapid lesion detection. These advancements reflect Lantheus's commitment to innovative diagnostics and therapeutics in oncology.
Lantheus Holdings has announced its Inaugural Investor Day, scheduled for May 17, 2022, where it will outline its long-term growth strategy and financial targets. The event will feature updates from the management team on key commercial products and development assets. CEO Mary Anne Heino expressed enthusiasm for providing insights into their business and growth strategies aimed at delivering long-term value for patients and shareholders. The live webcast will be accessible for replay post-event.
Lantheus Holdings (NASDAQ: LNTH) released findings from a retrospective study analyzing the use of its PYLARIFY® AI in monitoring treatment response in prostate cancer patients. The study demonstrated that changes in PSMA scan indices correlated significantly with prostate-specific antigen (PSA) responses post-androgen deprivation therapy. Patients exhibited a 97% average decline in PSA levels, paired with significant reductions in PSMA indices in lymph nodes and bone. These results suggest PYLARIFY AI may enhance the quantification of disease burden and response to therapy in prostate cancer management.